Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/ern.11.203PMID 22288667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease

  2012cited by this paper
• Cost Effectiveness of Treatment of Parkinson’s Disease with Entacapone in the United States

  2012cited by this paper
• The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations

  2012cited by this paper
• The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinson’s Disease

  2011cited by this paper
• Targeting nicotinic receptors for Parkinson's disease therapy.

  2011cited by this paper
• An Update on Gene Therapy in Parkinson’s Disease

  2011cited by this paper
• Pros and cons of a prion-like pathogenesis in Parkinson's disease

  2011cited by this paper
• Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease

  2011cited by this paper
• Parkinson's disease, proteins, and prions: Milestones

  2011cited by this paper
• Neurotrophic factor therapy for Parkinson's disease.

  2010cited by this paper
• Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study

  2010cited by this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cited by this paper
• Late (Complicated) Parkinson's Disease

  2010cited by this paper
• Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

  2010cited by this paper
• Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

  2010cited by this paper
• Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study

  2010cited by this paper
• Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

  2010cited by this paper
• Adenosine A2A receptors and Parkinson's disease.

  2009cited by this paper
• Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

  2009cited by this paper
• Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis

  2009cited by this paper
• Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

  2009cited by this paper
• Levodopa in the treatment of Parkinson’s disease

  2009cited by this paper
• Levodopa-related wearing-off in Parkinson's disease: identification and management.

  2009cited by this paper
• Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

  2009cited by this paper
• Adherence to antiparkinson medication in a multicenter European study

  2009cited by this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cited by this paper
• Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo® 200) in the treatment of Parkinson’s disease: a case series

  2009cited by this paper
• What’s in the pipeline for the treatment of Parkinson’s disease?

  2008cited by this paper
• Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

  2008cited by this paper
• Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease

  2008cited by this paper
• Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD

  2008cited by this paper
• Should levodopa dose be reduced when switched to stalevo?

  2008cited by this paper
• Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

  2007cited by this paper
• The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.

  2007cited by this paper
• Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing‐off

  2007cited by this paper
• [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].

  2006cited by this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  2006cited by this paper
• Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

  2006cited by this paper
• Patient satisfaction with switching to Stalevo: an open‐label evaluation in PD patients experiencing wearing‐off (Simcom Study)

  2006cited by this paper
• Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

  2006cited by this paper
• Prospektive Erfassung der direkten und indirekten Kosten des idiopathischen Parkinson-Syndroms

  2006cited by this paper
• The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

  2006cited by this paper
• An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off

  2005cited by this paper
• Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off

  2005cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• Safety and tolerability of COMT inhibitors

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

  2004cited by this paper
• Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

  2004cited by this paper
• Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

  2004cited by this paper
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• Levodopa in the treatment of Parkinson's disease: Current controversies

  2004cited by this paper
• Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

  2004cited by this paper
• Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study

  2003cited by this paper
• The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

  2003cited by this paper
• Direct economic impact of Parkinson's disease: A research survey in the United Kingdom

  2003cited by this paper
• Economic burden and quality of life impairment increase with severity of PD.

  2003cited by this paper
• [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease

  2002cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines

  2002cited by this paper
• Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study)

  2002cited by this paper
• Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

  2002cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

  2001cited by this paper
• Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

  2000cited by this paper
• Pathophysiology of the basal ganglia in Parkinson's disease.

  2000cited by this paper
• Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group

  2000cited by this paper
• Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT.

  2000cited by this paper
• Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• The evolution and origin of motor complications in Parkinson's disease.

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Health related quality of life in Parkinson's disease: a prospective longitudinal study

  2000cited by this paper
• Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

  2000cited by this paper
• Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint

  1999cited by this paper
• Parkinson's disease. Second of two parts.

  1998cited by this paper
• Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications

  1998cited by this paper
• Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations

  1998cited by this paper
• The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism.

  1998cited by this paper
• Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patients

  1997cited by this paper
• Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease

  1997cited by this paper
• Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.

  1996cited by this paper
• The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism

  1994cited by this paper
• General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.

  1994cited by this paper
• Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

  1994cited by this paper
• Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

  1994cited by this paper
• Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

  1994cited by this paper
• The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

  1993cited by this paper
• COMPARISONS OF THERAPEUTIC EFFECTS OF LEVODOPA, LEVODOPA AND SELEGILINE, AND BROMOCRIPTINE IN PATIENTS WITH EARLY, MILD PARKINSONS-DISEASE - 3-YEAR INTERIM-REPORT

  1993cited by this paper
• Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

  1993cited by this paper
• Frequency and Cause of Parkinson’s Disease

  1992cited by this paper
• Young‐onset Parkinson's disease

  1991cited by this paper
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• Parkinson's disease: a clinical review.

  1974cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• Clinical Interventions in Aging Dovepress Levodopa in the Treatment of Parkinson's Disease: an Old Drug Still Going Strong

  year unknowncited by this paper

• Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson’s disease experiencing wearing off

  2025cites this paper
• Dopaminergic system and neurons: Role in multiple neurological diseases.

  2024cites this paper
• Elevated Ghrelin Promotes Hippocampal Ghrelin Receptor Defects in Humanized Amyloid-β Knockin Mice During Aging

  2023cites this paper
• A Smartphone-Based Fluorescent Electronic Tongue for Tracing Dopaminergic Agents in Human Urine.

  2021cites this paper
• Rabies Virus Glycoprotein (RVG29)-linked microRNA-124-loaded Polymeric Nanoparticles Inhibit Neuroinflammation in a Parkinson's disease Model.

  2019cites this paper
• Predicting Motor Sequence Learning in People With Parkinson Disease

  2019cites this paper
• Scaling behavior of drug transport and absorption in in silico cerebral capillary networks

  2018cites this paper
• Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation

  2018cites this paper
• Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia

  2018cites this paper
• Medical and surgical management of advanced Parkinson's disease

  2018cites this paper
• Ultrasound‐triggered effects of the microbubbles coupled to GDNF‐ and Nurr1‐loaded PEGylated liposomes in a rat model of Parkinson's disease

  2018cites this paper
• Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD).

  2017cites this paper
• Chapter 6 – Parkinson’s disease

  2017cites this paper
• Non-dopamine receptor ligands for the treatment of Parkinson’s disease. Insight into the related chemical/property space

  2016cites this paper
• The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis

  2016cites this paper
• Does Dopamine Replacement Medication Affect Postural Sequence Learning in Parkinson's Disease?

  2015cites this paper
• Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

  2015cites this paper
• Does Dopamine Replacement Medication Affect Postural Sequence Learning in Parkinson’s Disease?

  2015cites this paper
• Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.

  2015cites this paper
• Willingness to pay for a new drug delivery in Parkinson patients

  2014cites this paper
• Nocturnal manifestations of Parkinson’s disease and atypical Parkinsonism

  2014cites this paper
• A Case Study of a Taeeumin Patient with Advanced Parkinson's Disease Diagnosed as Dry-heat Symptomatic Pattern

  2013cites this paper
• Angiopep-Conjugated Nanoparticles for Targeted Long-Term Gene Therapy of Parkinson’s Disease

  2013cites this paper
• Daily physical function and frailty in persons with Parkinson's disease : a focus on females

  2013cites this paper
• Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications

  2013cites this paper